The vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen — when the vaccine was given as a half dose, followed by a full dose at least a month later — and 62% efficacy in a second regimen — when two full doses were given at least a month apart.
That averages to a 70% efficacy, AstraZeneca said.
It is not yet clear why the two dosages produced such different results.
When people were given the smaller dose, the number of asymptomatic infections dropped, indicating a difference in transmission, Professor Andrew Pollard, the trial’s lead investigator at Oxford, said in a call with journalists on Monday.
“What we’ve always tried to do with a vaccine is fool the immune system into thinking that there’s a dangerous infection there that it needs to respond to — but doing it in a very safe way,” Pollard explained. “So we get the immune response and we get the immune memory … waiting and ready if the pathogen itself is then encountered.”
It may be that the best way of “kicking the immune system into action” is to give the body a small amount of the vaccine to begin with — and then follow up with a larger amount, but as the data on that method is preliminary, there is still more work to do, Pollard said.
Pollard addressed the efficacy differences between those other trials on Monday, explaining that AstraZeneca had used slightly different protocols to measure the disease that included all aspects of the disease — including mild cases — which are harder to predict.
He said that the results of the trials were “exciting” and demonstrated that they had an “effective vaccine that will save many lives.”
No participants who received the vaccine were hospitalized or reported suffering severe cases of the virus, the company said in a statement on Monday.
Crucially, the AstraZeneca vaccine can be distributed and administered within existing healthcare systems, as it can be stored, transported and handled in normal refrigerated conditions (from 2-8 degrees Celsius, or 36-46 degrees Fahrenheit) for at least six months, the company said.
It will also be cheaper than rival coronavirus vaccines from makers Pfizer and Moderna. AstraZeneca has pledged to “ensure broad and equitable access to the vaccine at no profit for the duration of the pandemic.”
The company said it was making “rapid progress” in manufacturing, with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval.
AstraZeneca said it would “immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval,” adding that it will seek emergency-use listing from the World Health Organization to accelerate vaccine availability in low-income countries.
“The encouraging news is that greater protection at lower dose may mean that more people can be vaccinated with the same amount of vaccines, and that this vaccine can be stored easily at regular fridge temperature,” Piot said, noting that it would also help with equitable access to the vaccine globally.
‘Good news for everyone’
The news was welcomed by British Prime Minister Boris Johnson, who described the announcement as “incredibly exciting news” in a tweet on Monday.
The UK’s Health Secretary Matt Hancock told the BBC it was “very good news for everyone,” and that — subject to regulatory approval — he expected most doses to be distributed to the public in the new year. The UK government has already ordered 100 million doses of the vaccine.
On Monday, AstraZeneca’s operations chief executive Pam Cheng said 20 million doses would be available in the UK by the end of the year, with an extra 70 million more available there by the end of March.
On Friday, AstraZeneca told CNN that the company had already delivered four million vials of its vaccine candidate to the UK government, and that millions more frozen doses were ready to be sent.
Speaking to journalists on Monday, Pollard stressed that if the world is to get back to normal, global vaccination is key. He said that process would have to be a collaborative effort.
Dr Charlie Weller, Head of Vaccines at the UK research charity Wellcome agreed.
“Beating Covid-19 will depend on global collaboration,” Weller told the Science Media Centre, adding that “the incredible scientific progress being made will be for nothing if global governments do not make more money available, and urgently.”
Trials of the AstraZeneca Oxford vaccine were carried out around the world, including in the UK, the US, Japan, Russia, South Africa, Kenya and several Latin American countries.
At 70%, the AstraZeneca vaccine’s average efficacy is greater than the level of efficacy that the US Food and Drug Administration aimed for, which was at least 50% efficacy.
This article is auto-generated by Algorithm Source: rss.cnn.com